AR063971A1 - Metodo para tratar hipercolesterolemia - Google Patents

Metodo para tratar hipercolesterolemia

Info

Publication number
AR063971A1
AR063971A1 ARP070105237A ARP070105237A AR063971A1 AR 063971 A1 AR063971 A1 AR 063971A1 AR P070105237 A ARP070105237 A AR P070105237A AR P070105237 A ARP070105237 A AR P070105237A AR 063971 A1 AR063971 A1 AR 063971A1
Authority
AR
Argentina
Prior art keywords
methods
antisense
individual
compounds
antisense compounds
Prior art date
Application number
ARP070105237A
Other languages
English (en)
Inventor
Diane Tribble
Mark J Graham
Andrew T Watt
Sanjay Bhanot
Susan M Freier
Rosanne M Crooke
Tarbet Kristina Lemonidis
Original Assignee
Isis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc
Publication of AR063971A1 publication Critical patent/AR063971A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0375—Animal model for cardiovascular diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos antisentido y métodos para disminuir LDL-C en un individuo que tiene LDL-C elevado. Adicionalmente compuestos antisentido y métodos para tratar hipercolesterolemia, o alternativamente para tratar o prevenir ateroesclerosis. Además compuestos y métodos para disminuir el riesgo de enfermedad cardíaca coronaria. Tales métodos incluyen administrar a un individuo que necesita del tratamiento un compuesto antisentido dirigido a un ácido nucleico PCSK9. Los compuestos antisentido administrados incluyen oligonucleotidos antisentido gapmer.
ARP070105237A 2006-11-27 2007-11-26 Metodo para tratar hipercolesterolemia AR063971A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86739506P 2006-11-27 2006-11-27
US91289207P 2007-04-19 2007-04-19
US98628607P 2007-11-07 2007-11-07

Publications (1)

Publication Number Publication Date
AR063971A1 true AR063971A1 (es) 2009-03-04

Family

ID=40261579

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070105237A AR063971A1 (es) 2006-11-27 2007-11-26 Metodo para tratar hipercolesterolemia

Country Status (3)

Country Link
AR (1) AR063971A1 (es)
CL (1) CL2007003405A1 (es)
PE (1) PE20081656A1 (es)

Also Published As

Publication number Publication date
CL2007003405A1 (es) 2008-07-11
PE20081656A1 (es) 2008-10-24

Similar Documents

Publication Publication Date Title
MX2009005527A (es) Metodos para el tratamiento de hipercolesterolemia.
WO2009148605A3 (en) Methods for treating hypercholesterolemia
AR083878A1 (es) Terapia antidiabetica vasoprotectora y cardioprotectora, linagliptina, metodo de tratamiento
WO2007100675A3 (en) Collagenase for treating cellulite
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
NI201000105A (es) Régimen de dosificación asociado con ésteres de paliperidona inyectables de acción prolongada.
WO2021050953A8 (en) Compositions and methods for the delivery of therapeutic biologics for treatment of disease
AR055038A1 (es) Metodo y compuesto para tratar enfermedades vasculares perifericas
WO2007089945A3 (en) Treating diseases by targeting silt3
AR075423A1 (es) Composicion farmaceutica que comprende un inhibidor de sglt-2, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y sus usos
CL2013003105A1 (es) Compuestos de microarn que comprende secuencias de nucleósidos modificados, inhibidores de mir-21; usos de los compuestos para modular la actividad de mir -21 y para preparar un medicamento para tratar fibrosis, heridas o cancer
MX2010012860A (es) Metodos para tratar cancer del sistema nervioso central.
CY1112397T1 (el) Συνδυασμενη θεραπεια για την αντιμετωπιση του καρκινου
BRPI0412909A (pt) uso de rnai inibindo atividade de parp para a fabricação de um medicamento para o tratamento de cáncer
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
CL2011002690A1 (es) Uso de un compuestos especificos derivados de pirimidin-2,4-diamina, inhibidores de pkc-teta para tratar un trastorno inmunologico o la aterosclerosis.
WO2007029249A3 (en) Oligoribonucleotides and methods of use thereof for treatment of cardiovascular diseases
AR087918A1 (es) Tratamientos combinados que comprenden antagonistas de c-met y antagonistas de b-raf
CL2011000814A1 (es) Uso de auna mikacina liposomal que comprende un lipido y amikacina para preparar un medicamento util para el tratamiento de un desorden pulmonar en un paciente.
AR062658A1 (es) Terapias de combinacion para artritis reumatoide
CO2018004684A2 (es) Métodos para tratar la epilepsia
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
MX2008013017A (es) Tratamiento de malignidades hematologicas con fts y un inhibidor de tirosina cinasa de bcr-abl.
WO2007100590A3 (en) Methods for treating cellulite
EA201591233A1 (ru) Состав-депо для инъекций, включающий оптически активный толваптан, и способ его получения

Legal Events

Date Code Title Description
FB Suspension of granting procedure